The N-terminal of GSDMA3 can induce pyroptosis and release IL-18, and increase the inhibition of tumor cells mediated by T cells. PD-L1 can regulate GSDMC. Gmd and GSDMD can be used as biomarkers for anti-PD-1 therapy. The gene discussed is IL18; the disease is neoplasm.